Lv31
280 积分 2024-09-19 加入
Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments
5小时前
待确认
Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey
6小时前
已完结
Permeability enhancer incorporated oral nanosuspension of ARV-825 PROTAC for Glioblastoma treatment
6天前
已完结
Advancements in Nanosuspension Technology for Drug Delivery
12天前
已完结
Improvement of aqueous solubility and oral bioavailability of luteolin: a nanosuspension approach
12天前
已完结
Nanosuspensions: A new era of targeted therapeutics
12天前
已完结
Drug Release from Surfactant-Containing Amorphous Solid Dispersions: Mechanism and Role of Surfactant in Release Enhancement
1个月前
已完结
Role of surfactants in improving release from higher drug loading amorphous solid dispersions
1个月前
已完结
Exploring the impact of material selection on the efficacy of hot-melt extrusion
1个月前
已完结
Critical In Vitro Characterization Methods of Lipid-Based Formulations for Oral Delivery: a Comprehensive Review
1个月前
已完结
皖公网安备34019202002308
